The Retinal Vein Occlusion (RVO) market is poised for substantial growth, driven by the increasing prevalence of retinal vein occlusion. Rising awareness about the importance of early diagnosis and advanced treatment options is expected to boost market expansion. The development and approval of novel therapeutic agents, such as anti-VEGF drugs and corticosteroids, are enhancing treatment efficacy and improving patient outcomes, further propelling market growth.
However, the high costs associated with these advanced treatments and the limited availability of skilled healthcare professionals, particularly in developing regions, pose significant restraints. Market trends indicate a growing emphasis on personalized medicine and the integration of telemedicine services to enhance access to care.
Additionally, ongoing clinical trials and research into gene therapy and regenerative medicine are opening new opportunities for innovation. Despite these challenges, the overall outlook for the RVO market remains positive, with a strong focus on advancing treatment modalities and improving patient care.
Increasing regulatory approval for retinal vein occlusion (RVO) treatment products is expected to act as a significant driver for the RVO market over the forecast period. Regulatory approvals from authoritative bodies such as the FDA and EMA can expedite the market entry of new and innovative treatments, allowing pharmaceutical companies to bring their products to patients more quickly and efficiently
This not only accelerates commercialization but also expands the range of treatment options available to healthcare providers and patients, leading to improved patient outcomes and higher satisfaction. Additionally, regulatory approvals often enhance the credibility and trust in the safety and efficacy of these treatments, which can increase their adoption rates and influence insurance coverage and reimbursement policies, making them more accessible and affordable
For instance, in March 2024, Chugai Pharmaceutical Co., Ltd. announced that it had obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for anti-VEGF/anti-Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120, for an additional indication of the treatment of macular edema associated with retinal vein occlusion (RVO). Vabysmo is the first bispecific antibody in Japan for the treatment of this disease
For instance, in October 2023, Genentech, a member of the Roche Group today that the U.S. Food and Drug Administration (FDA) had approved Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
| Attribute | Details |
|---|---|
| Retinal Vein Occlusion Market Drivers |
|
Rising awareness about retinal vein occlusion (RVO) is expected to drive market growth over the forecast period. Increased awareness among both - healthcare professionals and the general public is crucial for early detection and timely treatment of RVO, which can significantly improve patient outcomes. Educational programs and public health initiatives play a vital role in disseminating information about the symptoms, risk factors, and available treatment options for RVO
As more people become informed, they are more likely to seek medical attention at the first signs of symptoms, leading to earlier diagnosis and intervention. This, in turn, can reduce the severity of the condition and the need for more invasive or costly treatments. Additionally, healthcare professionals who are better educated about RVO are more likely to adopt the latest diagnostic tools and treatment modalities, enhancing the overall quality of care
Increased awareness also fosters a greater demand for advanced treatments, encouraging pharmaceutical companies and researchers to invest in the development of new and more effective therapies. Overall, the combination of heightened public and professional awareness and education is expected to significantly contribute to the growth of the RVO market over the forecast period.
Branch Retinal Vein Occlusion (BRVO) is expected to dominate the retinal vein occlusion (RVO) market over the forecast period due to several key factors. Firstly, BRVO has a higher prevalence compared to Central Retinal Vein Occlusion (CRVO), accounting for a larger proportion of RVO cases.
This higher incidence rate translates into a larger patient pool, driving demand for BRVO treatments. For instance, according to an article published in A Journal of Clinical Medicine, over 20 million individuals suffer from BRVO, a figure expected to rise due to population aging globally
Additionally, BRVO generally has a better prognosis and fewer complications, making it more treatable and manageable. Effective treatments such as anti-VEGF therapies (e.g., ranibizumab, aflibercept) and corticosteroid implants (e.g., dexamethasone intravitreal implant) have shown significant success in improving visual outcomes and reducing macular edema, leading to higher adoption rates. Increased awareness and early diagnosis, facilitated by public health initiatives and advanced diagnostic tools like optical coherence tomography (OCT) and fluorescein angiography, are also contributing to the dominance of BRVO in the market
The pharmacological treatment sub-segment is expected to dominate the retinal vein occlusion (RVO) market over the forecast period due to several key factors. Firstly, pharmacological treatments, particularly anti-VEGF therapies such as ranibizumab (Lucentis), aflibercept (Eylea), and brolucizumab (Beovu) have become the gold standard for managing RVO. These treatments have been extensively studied and have demonstrated significant efficacy in reducing macular edema and improving visual outcomes, leading to high adoption rates among healthcare providers.
Increasing product approvals for pharmacological treatments are expected to drive the global retinal vein occlusion (RVO) market over the forecast period. Regulatory approvals from bodies such as the FDA and EMA for new and improved pharmacological treatments, such as anti-VEGF therapies and corticosteroid implants, can significantly accelerate market growth. For instance, in July 2024, Hoffmann-La Roche AG (Roche Canada) announced that Health Canada had authorized Vabysmo (faricimab injection) for the treatment of macular edema secondary to retinal vein occlusion (RVO) ‘
| Attribute | Detail |
|---|---|
| Leading Region | North America |
The global retinal vein occlusion (RVO) market is dominated by North America due to several key factors. Firstly, North America boasts a highly advanced healthcare infrastructure, which includes state-of-the-art diagnostic tools and treatment facilities. This infrastructure enables early and accurate diagnosis of RVO, leading to more effective and timely treatment.
The region is also characterized by a high level of awareness and education about retinal vein occlusion among both - healthcare providers and the general public, which facilitates early intervention and better patient outcomes. Robust reimbursement policies and comprehensive insurance coverage in North America make advanced retinal vein occlusion treatments more accessible and affordable, further driving market growth. Additionally, the presence of leading pharmaceutical companies and research institutions in the region fosters a strong focus on research and development (R&D), leading to the continuous introduction of innovative treatments and technologies
The high prevalence of lifestyle-related conditions such as hypertension and diabetes, which are significant risk factors for retinal vein occlusion, also contributes to the higher incidence of the condition in North America. These factors, combined with a strong healthcare ecosystem and a commitment to advancing medical care, position North America as the dominant region in the global retinal vein occlusion market.
The leading players in the retinal vein occlusion market include Bayer AG, Alimera Sciences, AbbVie, Annexin Pharmaceuticals AB, F. Hoffmann-La Roche AG, Novartis AG, IRIDEX Corporation, Lumenis, Nidek Co., Ltd. and Regeneron Pharmaceuticals, Inc.
Each of these players have been have been profiled in the retinal vein occlusion market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Details |
|---|---|
| Size in 2023 | US$ 2.8 Bn |
| Forecast Value in 2034 | More than US$ 5.5 Bn |
| CAGR | 6.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global retinal vein occlusion market was valued at US$ 2,779.0 Mn 2.8 Bn in 2023.
The global retinal vein occlusion market business is projected to cross US$ 5,578.8 Mn 5.56 Bn by the end of 2034.
Increasing regulatory approval for retinal vein occlusion (RVO) treatment products and rising awareness and education.
The CAGR is anticipated to be 6.7% from 2024 to 2034.
North America is expected to account for the largest share from 2024 to 2034.
Bayer AG, Alimera Sciences, AbbVie, Annexin Pharmaceuticals AB, F. Hoffmann-La Roche AG, Novartis AG, IRIDEX Corporation, Lumenis, Nidek Co., Ltd. and Regeneron Pharmaceuticals, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Retinal Vein Occlusion Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Retinal Vein Occlusion Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Regulatory Scenario
5.2. PESTLE Analysis
5.3. Healthcare Expenditure by Region/Country (Health spending Total, US dollars/capita, 2022)
5.4. Go-to-Market Strategies for Retinal Vein Occlusion Market
5.5. Value Chain Analysis
5.6. Treatment Algorithm
5.7. Key Industry Events
6. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Disease Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Disease Type, 2020-2034
6.3.1. Central Retinal Vein Occlusion
6.3.2. Branch Retinal Vein Occlusion
6.4. Market Attractiveness By Disease Type
7. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Treatment Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Treatment Type, 2020-2034
7.3.1. Pharmacological Treatment
7.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
7.3.1.2. Corticosteroid Drugs
7.3.2. Laser Treatment
7.3.2.1. Panretinal Photocoagulation
7.3.2.2. Focal Laser
7.3.3. Vitrectomy
7.4. Market Attractiveness By Treatment Type
8. Global Retinal Vein Occlusion Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020-2034
8.3.1. Hospitals and Ambulatory Surgical Centers
8.3.2. Ophthalmology Clinics
8.3.3. Retail Pharmacies
8.3.4. Others
8.4. Market Attractiveness By End-user
9. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Region
10. North America Retinal Vein Occlusion Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Disease Type, 2020-2034
10.2.1. Central Retinal Vein Occlusion
10.2.2. Branch Retinal Vein Occlusion
10.3. Market Value Forecast By Treatment Type, 2020-2034
10.3.1. Pharmacological Treatment
10.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
10.3.1.2. Corticosteroid Drugs
10.3.2. Laser Treatment
10.3.2.1. Panretinal Photocoagulation
10.3.2.2. Focal Laser
10.3.3. Vitrectomy
10.4. Market Value Forecast By End-user, 2020-2034
10.4.1. Hospitals and Ambulatory Surgical Centers
10.4.2. Ophthalmology Clinics
10.4.3. Retail Pharmacies
10.4.4. Others
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Disease Type
10.6.2. By Treatment Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Retinal Vein Occlusion Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Disease Type, 2020-2034
11.2.1. Central Retinal Vein Occlusion
11.2.2. Branch Retinal Vein Occlusion
11.3. Market Value Forecast By Treatment Type, 2020-2034
11.3.1. Pharmacological Treatment
11.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
11.3.1.2. Corticosteroid Drugs
11.3.2. Laser Treatment
11.3.2.1. Panretinal Photocoagulation
11.3.2.2. Focal Laser
11.3.3. Vitrectomy
11.4. Market Value Forecast By End-user, 2020-2034
11.4.1. Hospitals and Ambulatory Surgical Centers
11.4.2. Ophthalmology Clinics
11.4.3. Retail Pharmacies
11.4.4. Others
11.5. Market Value Forecast By Country / Sub-region, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Disease Type
11.6.2. By Treatment Type
11.6.3. By End-user
11.6.4. By Country / Sub-region
12. Asia Pacific Retinal Vein Occlusion Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Disease Type, 2020-2034
12.2.1. Central Retinal Vein Occlusion
12.2.2. Branch Retinal Vein Occlusion
12.3. Market Value Forecast By Treatment Type, 2020-2034
12.3.1. Pharmacological Treatment
12.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
12.3.1.2. Corticosteroid Drugs
12.3.2. Laser Treatment
12.3.2.1. Panretinal Photocoagulation
12.3.2.2. Focal Laser
12.3.3. Vitrectomy
12.4. Market Value Forecast By End-user, 2020-2034
12.4.1. Hospitals and Ambulatory Surgical Centers
12.4.2. Ophthalmology Clinics
12.4.3. Retail Pharmacies
12.4.4. Others
12.5. Market Value Forecast By Country / Sub-region, 2020-2034
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Disease Type
12.6.2. By Treatment Type
12.6.3. By End-user
12.6.4. By Country / Sub-region
13. Latin America Retinal Vein Occlusion Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Disease Type, 2020-2034
13.2.1. Central Retinal Vein Occlusion
13.2.2. Branch Retinal Vein Occlusion
13.3. Market Value Forecast By Treatment Type, 2020-2034
13.3.1. Pharmacological Treatment
13.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
13.3.1.2. Corticosteroid Drugs
13.3.2. Laser Treatment
13.3.2.1. Panretinal Photocoagulation
13.3.2.2. Focal Laser
13.3.3. Vitrectomy
13.4. Market Value Forecast By End-user, 2020-2034
13.4.1. Hospitals and Ambulatory Surgical Centers
13.4.2. Ophthalmology Clinics
13.4.3. Retail Pharmacies
13.4.4. Others
13.5. Market Value Forecast By Country / Sub-region, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Disease Type
13.6.2. By Treatment Type
13.6.3. By End-user
13.6.4. By Country / Sub-region
14. Middle East & Africa Retinal Vein Occlusion Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Disease Type, 2020-2034
14.2.1. Central Retinal Vein Occlusion
14.2.2. Branch Retinal Vein Occlusion
14.3. Market Value Forecast By Treatment Type, 2020-2034
14.3.1. Pharmacological Treatment
14.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
14.3.1.2. Corticosteroid Drugs
14.3.2. Laser Treatment
14.3.2.1. Panretinal Photocoagulation
14.3.2.2. Focal Laser
14.3.3. Vitrectomy
14.4. Market Value Forecast By End-user, 2020-2034
14.4.1. Hospitals and Ambulatory Surgical Centers
14.4.2. Ophthalmology Clinics
14.4.3. Retail Pharmacies
14.4.4. Others
14.5. Market Value Forecast By Country / Sub-region, 2020-2034
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Disease Type
14.6.2. By Treatment Type
14.6.3. By End-user
14.6.4. By Country / Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Alimera Sciences
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Abbivie
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Annexin Pharmaceuticals AB
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. F. Hoffmann-La Roche AG
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Novartis AG
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. IRIDEX Corporation
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Lumenis
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Nidek Co., Ltd.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Regeneron Pharmaceuticals, Inc.
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
List of Tables
Table 01: Global Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Disease Type, 2020-2034
Table 02: Global Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Treatment Type, 2020-2034
Table 03: Global Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Pharmacological Treatment, 2020-2034
Table 04: Global Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Laser Treatment, 2020-2034
Table 05: Global Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By End-user, 2020-2034
Table 06: Global Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Region, 2020-2034
Table 07: North America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 08: North America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 09: North America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Treatment Type, 2020-2034
Table 10: North America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Pharmacological Treatment, 2020-2034
Table 11: North America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Laser Treatment, 2020-2034
Table 12: North America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Europe Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Europe Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 15: Europe Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Treatment Type, 2020-2034
Table 16: Europe Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Pharmacological Treatment, 2020-2034
Table 17: Europe Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Laser Treatment, 2020-2034
Table 18: Europe Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 19: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 20: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 21: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Treatment Type, 2020-2034
Table 22: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Pharmacological Treatment, 2020-2034
Table 23: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Laser Treatment, 2020-2034
Table 24: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 25: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 26: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 27: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Treatment Type, 2020-2034
Table 28: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Pharmacological Treatment, 2020-2034
Table 29: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Laser Treatment, 2020-2034
Table 30: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 31: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 32: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by Disease Type, 2020-2034
Table 33: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Treatment Type, 2020-2034
Table 34: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Pharmacological Treatment, 2020-2034
Table 35: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Forecast, By Laser Treatment, 2020-2034
Table 36: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast, 2020-2034
Figure 02: Global Retinal Vein Occlusion Market Value Share, by Disease Type, 2023
Figure 03: Global Retinal Vein Occlusion Market Value Share, By Treatment Type, 2023
Figure 04: Global Retinal Vein Occlusion Market Value Share, by End-user, 2023
Figure 05: Global Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By Disease Type, 2023 and 2034
Figure 06: Global Retinal Vein Occlusion Market Share Analysis, By Disease Type, 2023
Figure 07: Global Retinal Vein Occlusion Market Share Analysis, By Disease Type, 2034
Figure 08: Global Retinal Vein Occlusion Market Attractiveness Analysis, By Disease Type, 2024-2034
Figure 09: Global Retinal Vein Occlusion Market Value (US$ Bn), by Central Retinal Vein Occlusion, 2020‒2034
Figure 10: Global Retinal Vein Occlusion Market Value Share Analysis, by Central Retinal Vein Occlusion, 2023 and 2034
Figure 11: Global Retinal Vein Occlusion Market Value (US$ Bn), by Branch Retinal Vein Occlusion, 2020‒2034
Figure 12: Global Retinal Vein Occlusion Market Value Share Analysis, by Branch Retinal Vein Occlusion, 2023 and 2034
Figure 13: Global Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By Treatment Type, 2023 and 2034
Figure 14: Global Retinal Vein Occlusion Market Share Analysis, By Treatment Type, 2023
Figure 15: Global Retinal Vein Occlusion Market Share Analysis, By Treatment Type, 2034
Figure 16: Global Retinal Vein Occlusion Market Attractiveness Analysis, By Treatment Type, 2024-2034
Figure 17: Global Retinal Vein Occlusion Market Value (US$ Bn), by Pharmacological Treatment, 2020‒2034
Figure 18: Global Retinal Vein Occlusion Market Value Share Analysis, by Pharmacological Treatment, 2023 and 2034
Figure 19: Global Retinal Vein Occlusion Market Value (US$ Bn), by Laser Treatment, 2020‒2034
Figure 20-: Global Retinal Vein Occlusion Market Value Share Analysis, by Laser Treatment, 2023 and 2034
Figure 21: Global Retinal Vein Occlusion Market Value (US$ Bn), by Vitrectomy, 2020‒2034
Figure 22: Global Retinal Vein Occlusion Market Value Share Analysis, by Vitrectomy, 2023 and 2034
Figure 23: Global Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By End-user, 2023 and 2034
Figure 24: Global Retinal Vein Occlusion Market Share Analysis, By End-user, 2023
Figure 25: Global Retinal Vein Occlusion Market Share Analysis, By End-user, 2034
Figure 26: Global Retinal Vein Occlusion Market Attractiveness Analysis, By End-user, 2024-2034
Figure 27: Global Retinal Vein Occlusion Market Value (US$ Bn), by Hospitals and Ambulatory Surgical Centers, 2020‒2034
Figure 28: Global Retinal Vein Occlusion Market Value Share Analysis, by Hospitals and Ambulatory Surgical Centers, 2023 and 2034
Figure 29: Global Retinal Vein Occlusion Market Value (US$ Bn), by Ophthalmology Clinics, 2020‒2034
Figure 30: Global Retinal Vein Occlusion Market Value Share Analysis, by Ophthalmology Clinics, 2023 and 2034
Figure 31: Global Retinal Vein Occlusion Market Value (US$ Bn), by Retail Pharmacies, 2020‒2034
Figure 32: Global Retinal Vein Occlusion Market Value Share Analysis, by Retail Pharmacies, 2023 and 2034
Figure 33: Global Retinal Vein Occlusion Market Value (US$ Bn), By Others, 2020‒2034
Figure 34: Global Retinal Vein Occlusion Market Value Share Analysis, by Others, 2023 and 2034
Figure 35: Global Retinal Vein Occlusion Market Value Share Analysis, by Region, 2023 and 2034
Figure 36: Global Retinal Vein Occlusion Market Share Analysis, by Region, 2023
Figure 37: Global Retinal Vein Occlusion Market Share Analysis, by Region, 2034
Figure 38: Global Retinal Vein Occlusion Market Attractiveness Analysis, by Region, 2023-2034
Figure 39: North America Retinal Vein Occlusion Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 40: North America Retinal Vein Occlusion Market Value Share Analysis, by Country, 2023 and 2034
Figure 41: North America Retinal Vein Occlusion Market Attractiveness Analysis, by Country, 2024-2034
Figure 42: North America Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 43: North America Retinal Vein Occlusion Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 44: North America Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By Treatment Type, 2023 and 2034
Figure 45: North America Retinal Vein Occlusion Market Attractiveness Analysis, By Treatment Type, 2024-2034
Figure 46: North America Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 47: North America Retinal Vein Occlusion Market Attractiveness Analysis, by End-user, 2024-2034
Figure 48: Europe Retinal Vein Occlusion Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 49: Europe Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 50: Europe Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 51: Europe Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 52: Europe Retinal Vein Occlusion Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 53: Europe Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By Treatment Type, 2023 and 2034
Figure 54: Europe Retinal Vein Occlusion Market Attractiveness Analysis, By Treatment Type, 2024-2034
Figure 55: Europe Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 56: Europe Retinal Vein Occlusion Market Attractiveness Analysis, by End-user, 2024-2034
Figure 57: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 58: Asia Pacific Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 59: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 60: Asia Pacific- Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 61: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 62: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By Treatment Type, 2023 and 2034
Figure 63: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, By Treatment Type, 2024-2034
Figure 64: Asia Pacific Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 65: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 67: Latin America Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 68: Latin America Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 69: Asia Pacific- Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 70: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 71: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By Treatment Type, 2023 and 2034
Figure 72: Latin America Retinal Vein Occlusion Market Attractiveness Analysis, By Treatment Type, 2024-2034
Figure 73: Latin America Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 74: Latin America Retinal Vein Occlusion Market Attractiveness Analysis, by End-user, 2024-2034
Figure 75: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 76: Middle East & Africa Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 77: Middle East & Africa Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 78: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by Disease Type, 2023 and 2034
Figure 79: Middle East & Africa Retinal Vein Occlusion Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 80: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, By Treatment Type, 2023 and 2034
Figure 81: Middle East & Africa Retinal Vein Occlusion Market Attractiveness Analysis, By Treatment Type, 2024-2034
Figure 82: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 83: Middle East & Africa Retinal Vein Occlusion Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Retinal Vein Occlusion Market
